Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle R Mahoney

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|February 19, 2008
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreasSteven Attia, Jill Kolesar, Michelle R Mahoney, et al.
International Seminars in Surgical Oncology : ISSO|November 10, 2004
Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment GroupAminah Jatoi, James Martenson, Michelle R Mahoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.
Targeted Oncology|December 13, 2016
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)Joleen M Hubbard, Michelle R Mahoney, William S Loui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortiumScott Okuno, William J Maples, Michelle R Mahoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II study of erlotinib in patients with advanced biliary cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.
International Journal of Gastrointestinal Cancer|June 10, 2003
CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) studySteven R Alberts, Paul A Fishkin, Lawrence J Burgart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)Frank A Sinicrope, Michelle R Mahoney, Harry H Yoon, et al.
Clinical Colorectal Cancer|August 8, 2007
Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248Steven R Alberts, George P Kim, Michelle R Mahoney, et al.
Clinical Colorectal Cancer|September 2, 2006
Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancerMichael J O'Connell, Daniel J Sargent, Harold E Windschitl, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|February 19, 2008
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreasSteven Attia, Jill Kolesar, Michelle R Mahoney, et al.
International Seminars in Surgical Oncology : ISSO|November 10, 2004
Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment GroupAminah Jatoi, James Martenson, Michelle R Mahoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.
Targeted Oncology|December 13, 2016
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)Joleen M Hubbard, Michelle R Mahoney, William S Loui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortiumScott Okuno, William J Maples, Michelle R Mahoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II study of erlotinib in patients with advanced biliary cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.
International Journal of Gastrointestinal Cancer|June 10, 2003
CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) studySteven R Alberts, Paul A Fishkin, Lawrence J Burgart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)Frank A Sinicrope, Michelle R Mahoney, Harry H Yoon, et al.
Clinical Colorectal Cancer|August 8, 2007
Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248Steven R Alberts, George P Kim, Michelle R Mahoney, et al.
Clinical Colorectal Cancer|September 2, 2006
Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancerMichael J O'Connell, Daniel J Sargent, Harold E Windschitl, et al.
Pageof 5